Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and Scrip Asks experts about prospects for pharma science and technology in 2022.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 February 2022, including: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and Scrip Asks experts about prospects for pharma science and technology in 2022.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms" - Scrip, 21 Feb, 2022.)

(Also see "AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data" - Scrip, 21 Feb, 2022.)

(Also see "Bayer's Faith In Pharma Pipeline Paying Off" - Scrip, 21 Feb, 2022.)

(Also see "A US Biosimilar Turning Point Approaches, With Work To Do" - Scrip, 17 Feb, 2022.)

(Also see "Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science" - Scrip, 17 Feb, 2022.)

 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC145965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel